factor receptor ( EGFR ) mutations, including EGFR S768I, L861Q , and G719× , based on data showing the efficacy of certain EGFR tyrosine kinase inhibitors (TKIs) for patients with these mutations. All the systemic therapy regimens have been
Search Results
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr., Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Jose M. Pacheco, Sandip P. Patel, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina Gregory, and Miranda Hughes
Gordon Taylor Moffat, Tao Wang, and Andrew G. Robinson
targeted therapy to driver mutations in EGFR and ALK have revolutionized management with the prolongation of profession-free and overall survivals. Additional targeted therapies include agents targeting MET , RET , ROS1 , KRAS , BRAF , and ERBB2
Gregory J. Riely, Jamie E. Chaft, Marc Ladanyi, and Mark G. Kris
The past 7 years have seen dramatic changes in our understanding of the pathogenesis and treatment of lung cancers. The clearest examples of these advances are erlotinib and gefitinib, the epidermal growth factor receptor (EGFR) tyrosine kinase
Charu Aggarwal, Neeta Somaiah, and George R. Simon
growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2)/neu kinase domains. 40 – 42 Slebos et al. 43 evaluated the relationship among KRAS activation, tumor characteristics, and survival in patients with NSCLC. Tumors positive
Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck Principal Investigator: Aarti Bhatia, MD, MPH Condition
Tayyaba Hasan
to PDT in prostate, pancreatic, and ovarian cancer cell models is discussed, featuring the roles of both vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) in guiding the selection of targeted agents to join PDT in
Céline Mascaux, Ming-Sound Tsao, and Fred R. Hirsch
( EGFR ) mutations received 150 mg of erlotinib for 1 year; ERCC1-negative patients received 4 courses of cisplatin/pemetrexed, whereas ERCC1-positive patients underwent follow-up. 4 These recent data are based on a small cohort of patients with a low
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
Featured Updates to the NCCN Guidelines
David S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Michael Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Renato G. Martins, Gregory A. Otterson, Sandip P. Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina Gregory, OCN, and Miranda Hughes
-line therapy with osimertinib for certain patients with metastatic NSCLC and EGFR mutations. However, the 2020 update of the guidelines has expanded the preference stratification categories to include all of the systemic therapy regimens. First
Mario E. Lacouture
made several key points about skin rash produced by different cancer therapies: Most patients taking EGFR inhibitors develop an acneiform rash on the face, scalp, and upper body, often within the first 4 weeks. This is associated with pruritus
Mona H. Cai, Yookyung Christy Choi, Athan Vasilopoulos, Alexander Liede, Sidney S. Lindsey, Leon Raskin, Ethan Truong, Jeremy Fricke, Stephen B. Gruber, and Peter J. Ansell
%), and EGFR tyrosine kinase inhibitor (TKI) (17%) compared with EGFR TKI, ICI, ICI+Chemo, platinum-based doublet (19%) and other targeted therapies (10%) in c-Met OE NEG patients. Conclusions: Patients with c-Met OE represent nearly a quarter of non
